SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“These preliminary third-quarter revenue results mark a significant inflection point for Scienture, demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“With Arbli(™) continuing to gain traction and REZENOPY(™) becoming our second commercial-stage product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth through the remainder of 2026 and into 2027.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“As we work to expand our distribution channels and drive commercial adoption, we believe our historically high gross margins will provide significant operating leverage, supporting our goal of achieving profitability in 2027.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings

“Our preliminary third-quarter revenues reflect the progress we have made in executing our commercial strategy and establishing Scienture as a growing specialty pharmaceutical company”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings

“Looking ahead, we see significant opportunities to further penetrate our addressable markets, particularly as we focus on increasing institutional adoption, expanding healthcare provider engagement and entering strategic commercial partnerships.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings

“With two differentiated FDA-approved products addressing important unmet needs commercialized, we believe Scienture is well-positioned to build a sustainable, high-value pharmaceutical business and deliver long-term value to shareholders.”